Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals

Drug Profile

Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals

Alternative Names: Arcalyst; IL-1-Cytokine-Trap; IL-1-Trap; Interleukin-1 Trap; KPL 914; RGN-303

Latest Information Update: 05 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Boston University; Charite - Universitatsmedizin Berlin; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes
  • Phase III Cardiovascular disorders
  • Phase II Urticaria
  • Phase I/II Systemic scleroderma
  • Discontinued Anaemia; Gout; Juvenile rheumatoid arthritis; Osteoarthritis; Polymyalgia rheumatica; Rheumatoid arthritis

Most Recent Events

  • 17 May 2019 Kiniksa Pharmaceuticals completes phase-II clinical trials in Cardiovascular disorders in USA (SC) (NCT03980522)
  • 16 Mar 2019 Efficacy and adverse event data from a phase II trial in Cardiovscular disorders (recurrent pericarditis) presented at the 68th Annual Scientific Session of the American College of Cardiology (ACC,
  • 07 Mar 2019 Kiniksa Pharmaceuticals completes enrolment in phase II trial for Cardiovascular disorders (in recurrent pericarditis) in USA before March 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top